TipRanks
Biocryst Pharmaceuticals (CH:BO1)
:BO1
Switzerland Market
BO1
BioCryst
RESEARCH TOOLSreports

BioCryst (BO1) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

BO1 Analyst Ratings

Strong Buy
8Ratings
Strong Buy
6 Buy
2 Hold
0 Sell
Based on 8 analysts giving stock ratings to
BioCryst
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BO1 Stock 12 Month Forecast

Average Price Target

―
Based on 8 Wall Street analysts offering 12 month price targets for BioCryst in the last 3 months. The average price target is CHF15.98 with a high forecast of CHF26.57 and a low forecast of CHF9.13. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF26.57Average Price TargetCHF15.98Lowest Price TargetCHF9.13
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CH:BO1
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF12.45
Buy
―
Reiterated
10/09/26
Bank of America Securities Keeps Their Buy Rating on BioCryst (BCRX)
RBC Capital Analyst forecast on CH:BO1
Brian Abrahams
RBC Capital
RBC Capital
CHF9.13
Hold
―
Reiterated
10/08/26
RBC Capital Sticks to Its Hold Rating for BioCryst (BCRX)
J.P. Morgan Analyst forecast on CH:BO1
Jessica Fye
J.P. Morgan
J.P. Morgan
CHF9.96→CHF10.79
Hold
―
Assigned
09/30/26
BioCryst price target raised to $13 from $12 at JPMorganBioCryst price target raised to $13 from $12 at JPMorgan
Needham Analyst forecast on CH:BO1
Serge Belanger
Needham
Needham
CHF13.28
Buy
―
Reiterated
09/08/26
Analysts' Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)
Evercore ISI Analyst forecast on CH:BO1
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
CHF14.11
Buy
―
Reiterated
08/10/26
BioCryst (BCRX) Gets a Buy from Evercore ISI
H.C. Wainwright Analyst forecast on CH:BO1
Andrew Fein
H.C. Wainwright
H.C. Wainwright
CHF26.57
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), BioCryst (NASDAQ: BCRX) and GH Research (NASDAQ: GHRS)
Wedbush Analyst forecast on CH:BO1
Laura Chico
Wedbush
Wedbush
CHF16.6
Buy
―
Reiterated
08/06/26
Wedbush Sticks to Their Buy Rating for BioCryst (BCRX)
TD Cowen Analyst forecast on CH:BO1
Stacy Ku
TD Cowen
TD Cowen
CHF24.91
Buy
―
Reiterated
08/05/26
Stacy Ku Reiterates Buy on BioCryst, Citing Strong Orladeyo Momentum, Durable Growth, and Billion-Dollar HAE Opportunities
Cantor Fitzgerald Analyst forecast on CH:BO1
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
CHF22.42→CHF24.08
Buy
―
Reiterated
06/30/26
Cantor Fitzgerald Sticks to Its Buy Rating for BioCryst (BCRX)
Citizens JMP Analyst forecast on CH:BO1
Jonathan Wolleben
Citizens JMP
Citizens JMP
CHF20.75→CHF23.25
Buy
―
Reiterated
05/07/26
BioCryst price target raised to $28 from $25 at CitizensBioCryst price target raised to $28 from $25 at Citizens
Barclays Analyst forecast on CH:BO1
Gena Wang
Barclays
Barclays
CHF9.13→CHF7.47
Hold
―
Reiterated
11/03/25
Barclays Sticks to Their Hold Rating for BioCryst (BCRX)
Jefferies Analyst forecast on CH:BO1
Maury Raycroft
Jefferies
Jefferies
CHF12.45
Buy
―
Reiterated
10/14/25
BioCryst's Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and Profitability
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CH:BO1
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF12.45
Buy
―
Reiterated
10/09/26
Bank of America Securities Keeps Their Buy Rating on BioCryst (BCRX)
RBC Capital Analyst forecast on CH:BO1
Brian Abrahams
RBC Capital
RBC Capital
CHF9.13
Hold
―
Reiterated
10/08/26
RBC Capital Sticks to Its Hold Rating for BioCryst (BCRX)
J.P. Morgan Analyst forecast on CH:BO1
Jessica Fye
J.P. Morgan
J.P. Morgan
CHF9.96→CHF10.79
Hold
―
Assigned
09/30/26
BioCryst price target raised to $13 from $12 at JPMorganBioCryst price target raised to $13 from $12 at JPMorgan
Needham Analyst forecast on CH:BO1
Serge Belanger
Needham
Needham
CHF13.28
Buy
―
Reiterated
09/08/26
Analysts' Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)
Evercore ISI Analyst forecast on CH:BO1
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
CHF14.11
Buy
―
Reiterated
08/10/26
BioCryst (BCRX) Gets a Buy from Evercore ISI
H.C. Wainwright Analyst forecast on CH:BO1
Andrew Fein
H.C. Wainwright
H.C. Wainwright
CHF26.57
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), BioCryst (NASDAQ: BCRX) and GH Research (NASDAQ: GHRS)
Wedbush Analyst forecast on CH:BO1
Laura Chico
Wedbush
Wedbush
CHF16.6
Buy
―
Reiterated
08/06/26
Wedbush Sticks to Their Buy Rating for BioCryst (BCRX)
TD Cowen Analyst forecast on CH:BO1
Stacy Ku
TD Cowen
TD Cowen
CHF24.91
Buy
―
Reiterated
08/05/26
Stacy Ku Reiterates Buy on BioCryst, Citing Strong Orladeyo Momentum, Durable Growth, and Billion-Dollar HAE Opportunities
Cantor Fitzgerald Analyst forecast on CH:BO1
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
CHF22.42→CHF24.08
Buy
―
Reiterated
06/30/26
Cantor Fitzgerald Sticks to Its Buy Rating for BioCryst (BCRX)
Citizens JMP Analyst forecast on CH:BO1
Jonathan Wolleben
Citizens JMP
Citizens JMP
CHF20.75→CHF23.25
Buy
―
Reiterated
05/07/26
BioCryst price target raised to $28 from $25 at CitizensBioCryst price target raised to $28 from $25 at Citizens
Barclays Analyst forecast on CH:BO1
Gena Wang
Barclays
Barclays
CHF9.13→CHF7.47
Hold
―
Reiterated
11/03/25
Barclays Sticks to Their Hold Rating for BioCryst (BCRX)
Jefferies Analyst forecast on CH:BO1
Maury Raycroft
Jefferies
Jefferies
CHF12.45
Buy
―
Reiterated
10/14/25
BioCryst's Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and Profitability
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
EHCEncompass Health
MDWDMediwound
OVIDOvid Therapeutics
ARDXArdelyx
STOKStoke Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioCryst

3 Months
Tazeen AhmadBank of America Securities
Success Rate
8/17 ratings generated profit
47%
Average Return
+0.26%
Copying Tazeen Ahmad's trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of +0.26% per trade.
1 Year
Tazeen AhmadBank of America Securities
Success Rate
11/17 ratings generated profit
65%
Average Return
+4.77%
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +4.77% per trade.
2 Years
Serge BelangerNeedham
Success Rate
15/25 ratings generated profit
60%
Average Return
+11.48%
Copying Serge Belanger's trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +11.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BO1 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
9
12
12
9
7
Buy
3
2
2
2
1
Hold
0
1
1
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
15
15
14
11
In the current month, BO1 has received 8 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. BO1 average Analyst price target in the past 3 months is 15.98.
Each month's total comprises the sum of three months' worth of ratings.

BO1 Financial Forecast

BO1 Earnings Forecast

Next quarter’s earnings estimate for BO1 is CHF0.07 with a range of -CHF0.01 to CHF0.14. The previous quarter’s EPS was CHF0.25. BO1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BO1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for BO1 is CHF0.07 with a range of -CHF0.01 to CHF0.14. The previous quarter’s EPS was CHF0.25. BO1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BO1 has Performed in-line its overall industry.

BO1 Sales Forecast

Next quarter’s sales forecast for BO1 is CHF137.43M with a range of CHF134.33M to CHF141.21M. The previous quarter’s sales results were CHF181.05M. BO1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BO1 has Performed in-line its overall industry.
Next quarter’s sales forecast for BO1 is CHF137.43M with a range of CHF134.33M to CHF141.21M. The previous quarter’s sales results were CHF181.05M. BO1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BO1 has Performed in-line its overall industry.

BO1 Stock Forecast FAQ

What is CH:BO1’s average 12-month price target, according to analysts?
Based on analyst ratings, Biocryst Pharmaceuticals’s 12-month average price target is 15.98.
    What is CH:BO1’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:BO1, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Biocryst Pharmaceuticals a Buy, Sell or Hold?
        Biocryst Pharmaceuticals has a consensus rating of Strong Buy, which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.
          What is Biocryst Pharmaceuticals’s share price target?
          The average share price target for Biocryst Pharmaceuticals is 15.98. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF26.57 ,and the lowest forecast is CHF9.13. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Biocryst Pharmaceuticals?
            Biocryst Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
              How can I buy shares of Biocryst Pharmaceuticals?
              To buy shares of CH:BO1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.